Figure 2 | British Journal of Cancer

Figure 2

From: Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR

Figure 2

Immune effector function of mAb 806 (○), chimeric IgGl antibody ch806 (•) and Isotype control cG250 (▾). (A) Complement-dependent cytotoxicity activity of 0–10 μg ml−1 antibody on target U87MG.de2-7 cells. Antibody-dependent cellular cytotoxity on target (B) A431 cells and (C) U87MG.de2-7 cells at effector-to-target cell ratio of 50 : 1 and antibody concentrations ranging from 0 to 10 μg ml−1. Mean (bars;±s.d.) percent cytotoxicity of triplicate determinations are presented. Representative results from three separate experiments are shown.

Back to article page